Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment
Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering
Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes
Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019
Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference